Inactive Instrument

SL Therapeutics, Inc. Share Price

A258540

KR7258540004

Latest news: SL Therapeutics, Inc.

13/10/22	StemLab Inc. announced that it has received KRW 1.5000006 billion in funding	CI
27/07/22	StemLab Inc. announced that it expects to receive KRW 1.5000006 billion in funding	CI
03/03/21	StemLab Inc. announced that it has received KRW 4 billion in funding	CI
23/02/21	StemLab Inc. announced that it expects to receive KRW 4 billion in funding	CI
26/10/20	StemLab Inc. announced that it has received KRW 5 billion in funding from DAYLI Partners Co., Ltd., IBK Capital Corporation, Blueotus Co., Ltd., DB Asset Management Co., Ltd.	CI
20/06/19	StemLab Inc. announced that it expects to receive KRW 5 billion in funding from DAYLI Partners Co., Ltd., IBK Capital Corporation, Blueotus Co., Ltd., DB Asset Management Co., Ltd. and another investor	CI
28/03/19	StemLab Inc. announced that it has received KRW 1.5 billion in funding	CI
13/03/19	StemLab Inc. announced that it expects to receive KRW 1.5 billion in funding	CI

More news

Press Releases: SL Therapeutics, Inc.

24/02/23

In volo con Leonardo: the new work orientation pathway of the STEMLab project

More press releases

Managers and Directors: SL Therapeutics, Inc.

Manager	Title	Age	Since
Jong-Seong Choi CEO	Chief Executive Officer	63	18/10/2022
Seung-Kwon Yoo PSD	President	61	28/03/2021
Jung-Il No AUD	Comptroller/Controller/Auditor	66	11/08/2024

Director	Title	Age	Since
Seung-Kwon Yoo BRD	Director/Board Member	61	-
Jong-Seong Choi BRD	Director/Board Member	63	-
Min-Woo Park BRD	Director/Board Member	58	28/03/2022

More insiders

SL Therapeutics Inc, formerly Stem Lab Inc, is a Korea-based company principally engaged in the manufacture and sale of biopharmaceuticals. The Company is principally engaged in the development, research, manufacture and sale of biopharmaceuticals such as stem cell culture mediums, stem cell treatment as well as others.

Employees

Sector

Pharmaceuticals

More about the company

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SL THERAPEUTICS, INC.	+61.97%	+49.35%	-	-	403K
ELI LILLY AND COMPANY	+4.24%	+12.26%	+69.28%	+152.71%	1,224B
JOHNSON & JOHNSON	+1.02%	+5.81%	+47.65%	+89.85%	662B
ABBVIE INC.	+1.54%	+4.48%	+30.78%	+110.34%	514B
ROCHE HOLDING AG	+0.30%	+3.33%	+54.34%	+67.38%	388B
MERCK & CO., INC.	+2.42%	+3.74%	+74.68%	+46.78%	361B
NOVARTIS AG	+1.42%	+5.28%	+36.29%	+59.23%	302B
ASTRAZENECA PLC	+6.44%	+9.09%	+11.51%	+36.92%	271B
AMGEN INC.	+2.11%	+7.95%	+62.39%	+80.16%	249B
GILEAD SCIENCES, INC.	+3.88%	+10.58%	+45.69%	+121.88%	205B
Average	+8.65%	+2.59%	+48.07%	+85.03%	464.09B
Weighted average by Cap.	+2.80%	+3.04%	+52.49%	+100.32%

SL Therapeutics, Inc. Share Price

Stocks

A258540

KR7258540004

Pharmaceuticals

Latest news: SL Therapeutics, Inc.

Press Releases: SL Therapeutics, Inc.

Quotes and Performance

Managers and Directors: SL Therapeutics, Inc.

Biopharmaceuticals

Company Profile